Read by QxMD icon Read

Current Clinical Pharmacology

Nusaiba Salisu, Fatima Sulaiman Aliyu, Hussaini Garba, Mikail Hudu Garba
BACKGROUND: Monosodium glutamate (MSG) is one of the most commonly used food additives for the enhancement of food taste and flavour. There are several conflicting reports of toxicity or otherwise safety of the compound, which raises a growing concern regarding the safety of monosodium glutamate as food additive. OBJECTIVE: In the present study, we sought to investigate the effect of monosodium glutamate on body weight, feed consumption, body temperature and some haematological parameters...
October 2, 2018: Current Clinical Pharmacology
Marwa Hassan, Mohamad A Ibrahim, Heba M Hafez, Mervat Z Mohamed, Nagwa M Zenhom, Hend M Abd Elghany
BACKGROUND: Cilostazol, a phosphodiesterase 3 inhibitor (PDE3I), is a platelet aggregation inhibitor and vasodilator that is useful for treating intermittent claudication. Experimental studies have shown that cilostazol has potent anti-inflammatory, anti-oxidant effects effects Objectives: Although the hepatoprotective effect cilostazol has been studied, the molecular mechanisms of such protection, including: the nuclear factor-erythroid 2-related factor 2 (Nrf2) / hemoxygenase (HO-1) and the phosphoinositide 3-kinase (PI3K) /serine/threonine kinase (Akt) pathways are not fully explored, which is the aim of this study...
September 3, 2018: Current Clinical Pharmacology
Sebastian Ezequiel Perez, Adriana Monica Carlucci
BACKGROUND: The molecular mechanism of silencing genes using small interference RNA is as particular and innovative phenomenon as the proposed delivery systems to release them. Recent advances in RNAi have resulted in the development of multiple siRNA candidates that are currently being evaluated in preclinical / clinical instances. SNALP®, Atuplex® and Rondel® technologies stand out; they are mainly based on polymers, ciclodextrins or lipids. METHODS: The objective of this work is to review the main features that Gene Therapy Medicinal Product under current clinical evaluation present from a pharmaceutical technology point of view; it tries to bring up theoretical concepts that give scientific support to the interpretation of data obtained during pharmaceutical development process...
August 29, 2018: Current Clinical Pharmacology
Kannan Sridharan, Gowri Sivaramakrishnan
OBJECTIVES: Osteogenesis imperfecta is a rare metabolic disorder associated with reduced mineralization of bone and corresponds to increased fracture risk. We carried out the present network meta-analysis comparing all the medical interventions for osteogenesis imperfecta. METHODS: Electronic databases were searched for randomized controlled clinical trials evaluating the use of drugs in patients with osteogenesis imperfecta. Percent change in BMD was the primary and fracture risk reduction and adverse events were the secondary outcome measures...
August 29, 2018: Current Clinical Pharmacology
Anahita Ahmadvand, Ameneh Yazdanfar, Fatemeh Yasrebifar, Younes Mohammadi, Reza Mahjoub, Maryam Mehrpooya
OBJECTIVES: Acne vulgaris is a common dermatologic disorder which results in psychological consequences. Inflammation plays an important role in the formation of acne lesions. Recently, many studies demonstrated anti-inflammatory effects of statins; thus, the aim of this study was to evaluate the efficacy of oral and topical Simvastatin as adjunct treatment in acne vulgaris. MATERIAL AND METHOD: In 76 patients with moderate to very severe acne vulgaris, beside antibiotic treatment including oral azithromycin (250 mg, 3 times a week, orally) and topical benzoyl peroxide gel (5%, once daily), oral group received 20mg/day of oral simvastatin and blank solution, topical group received simvastatin 1% topical solution and oral placebo, and placebo group received oral placebo and blank solution...
August 21, 2018: Current Clinical Pharmacology
Jaspreet Kaur Sidhu, Surjit Singh, Priyanka Kathuria
BACKGROUND: A questionnaire is a commonly used data collection method and is a very crucial part of the research. However, designing a questionnaire can be a daunting task for postgraduate students. METHODS: This manuscript illustrates the various steps required in questionnaire designing and provides an insight into the essentials of questionnaire construction and validation. Data from a questionnaire should be able to comprehend the objectives of the study; else it may lead to wrong interpretation or bias, decreased power of study and inability to generalize the study results...
August 7, 2018: Current Clinical Pharmacology
Dimitrios Patoulias, Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios Athyros, Michael Doumas
BACKGROUND: Sodium - glucose cotransporter 2 (SGTL-2) inhibitors are a new class of antidiabetics, which have been approved for the treatment of patients with type 2 diabetes mellitus (T2DM). Besides their beneficial metabolic effects, they exert favourable results in cardiovascular events and risk factors along with renoprotection. However, SGLT-2 inhibitors have not been yet approved as adjunct therapy to insulin in patients with type 1 diabetes mellitus (T1DM). This review aims at presenting both clinical and experimental data that reinforce the role of SGLT-2 inhibitors as adjunctive treatment in patients with T1DM along with the main restrictions of their use, namely diabetic ketoacidosis (DKA)...
August 7, 2018: Current Clinical Pharmacology
Thekkuttuparambil Ananthanarayanan Ajith
Dietary long chain polyunsaturated fatty acids belong to omega (ω)-3, -6 or -9 series. Both experimental and clinical studies demonstrated the beneficial effect of ω -3 fatty acids of fish oil, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) against human ailments including cardiovascular diseases and rheumatoid arthritis. They are metabolized in cyclooxygenase and lipooxygenase pathways and also by cytochrome P450 isozymes. Biological importance of DHA in the development of brain and retina are established as well...
August 7, 2018: Current Clinical Pharmacology
Paolo Usai-Satta, Massimo Bellini, Mariantonia Lai, Francesco Oppia, Francesco Cabras
BACKGROUND: Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal disorder. It is characterised by abdominal pain, bloating and changes in bowel habits that can have a serious impact on the patient's quality of life. Treatment strategies are based on the nature and severity of the symptoms, the degree of functional impairment of the bowel habits, and the presence of psychosocial disorders. The purpose of this review is to update our current knowledge of therapeutic approach of this disorder...
August 7, 2018: Current Clinical Pharmacology
Enzo Vicari, Giulia Malaguarnera, Beatrice Ornella Vicari, Mario Salmeri, Michele Salemi, Roberto Castiglione
BACKGROUND: Prostatitis is a recurrent urinary infection in males and is often difficult to cure. The aim of the study was to examine whether anti-inflammatory effects of enhanced drainage of prostatic secretions, obtained through two months treatment with a proteolytic enzyme mucoactive (PEM) compound (Serrazyme and other constituents), influenced qualitative or quantitative expressions of bacterial growth in seminal cultures. METHODS: 450 patients with prostatitis syndromes were randomized either to PEM therapy (intervention group) or to no treatment group...
August 2, 2018: Current Clinical Pharmacology
Mahmudul Hasan, Safaet Alam, Saikat Kumar Poddar
Cancer is one of the deadly diseases which is characterized by unchecked cell division or abnormal cell growth due to the incapability of cell cycle arrest. As the treatment for this is to kill the cancerous cells the main challenge for scientists is to direct the cell killing to cancerous cells while leaving the normal cells unharmed. Antibody-drug conjugates (ADC) are one such targeted anti-cancer therapy. It is an effective drug delivery system that utilizes the targeting action of antibody along with cell death by potent cytotoxic agent, linked up with one another by a linker molecule and thus helps to reduce toxicity to non-target cells, ensure broad therapeutic window and overcome multi-drug resistance...
August 1, 2018: Current Clinical Pharmacology
Cesare Gridelli, Paolo Antonio Ascierto, Francesco Grossi, Editta Baldini, Adolfo Favaretto, Maria Chiara Garassino, Alessandro Morabito, Maria Rita Migliorino, Antonio Rossi, Filippo de Marinis
BACKGROUND: Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for second- and third-line treatment of advanced NSCLC beyond old chemotherapy agents (docetaxel and pemetrexed) and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI, erlotinib). In particular, the new antiangiogenetics (nindetanib and ramucirumab) in combination with docetaxel and immunotherapy (nivolumab, pembrolizumab and atezolizumab) have been recently approved and represent new treatment options...
July 11, 2018: Current Clinical Pharmacology
Javad Akhtari, Alireza Tafazoli, Hassan Mehrad-Majd, Abdolkarim Mahrooz
RNA interference (RNAi) is a process for regulating the gene expression in which small interfering RNAs (siRNAs) silence target genes. siRNA-based therapy as a new molecular treatment approach, offers therapeutic prospects for many common diseases such as cancer and cardiovascular disorders. Nevertheless, the efficacy of siRNA delivery has, so far, remained a challenging issue. This is due to their easy degradation through the circulation system and the difficulties in the intracellular delivery to specific tissues where they silence the target genes...
July 9, 2018: Current Clinical Pharmacology
Ryuichi Sakate, Akiko Fukagawa, Yuri Takagaki, Hanayuki Okura, Akifumi Matsuyama
BACKGROUND: Drug development for rare diseases is challenging because very few patients suffer from such diseases, and thus it is difficult to obtain relevant data. In these difficult conditions, it must be informative to assess a trend of drug development so far, to plot a new strategy such as drug repositioning. OBJECTIVE: In this study, data from clinical trials belonging to three international registries were first outlined and compared. METHODS: ClinicalTrials...
June 3, 2018: Current Clinical Pharmacology
Jalal Pourahmad, Ahmad Salimi, Mosleh Razian
The current study investigates the cytotoxicity mechanism of common drugs with piperazine ring such as cetirizine, olanzapine and buspirone on human lymphocytes. The viability of lymphocytes, reactive oxygen species (ROS) formation, mitochondrial membrane potential (MMP) collapse, lysosomal integrity, content of glutathione and lipid peroxidation were determined. Buspirone and cetirizine showed more toxicity than olanzapine on human lymphocytes with an IC50 value of 200 μg/ml, after 6 h of incubation. Significant ROS formation, MMP collapse, lipid peroxidation, lysosomal damage and elevation of glutathione disulfide (GSSG) were observed in treated lymphocytes concentrations (4, 20, 40 µg/ml) of buspirone and cetirizine...
May 15, 2018: Current Clinical Pharmacology
Mahvash Zargar, Roshan Nikbakht, Mahzad Ahmadi
BACKGROUND: Postpartum haemorrhage (PPH) is an important cause of early maternal death which needs to be controlled. OBJECTIVE: This study was designed to compare the effect of intravenous tranexsmic acid (TXA) and prostaglandin analogue on reducing PPH resulted from uterine atony in women undergoing C section or vaginal delivery. METHOD: A randomized, triple-blind, placebo-controlled study was conducted on 248 pregnant women with PPH due to uterine atony who were randomly assigned into two groups of TXA as the intervention group (n=124) and prostaglandin analogue as the control group (n=124)...
May 6, 2018: Current Clinical Pharmacology
Nagendra S Ningaraj, Polluru L Reddy, Divya Khaitan
This review elucidates ongoing research, which show improved delivery of anticancer drugs alone and/ or enclosed in carriers collectively called nanomedicines to cross the Blood brain barrier (BBB) / blood-brain tumor barrier (BTB) to kill tumor cells and impact patient survival. We highlighted various advances in understanding the mechanism of BTB function that impact on anticancer therapeutics delivery. We discussed latest breakthroughs in developing pharmaceutical strategies, including nanomedicines and delivering them across BTB for brain tumor management and treatment...
April 12, 2018: Current Clinical Pharmacology
Dinesh Puri, Anil Bhandari, Praveen Kumar Gaur, Mohd Yasir, S Sadish Kumar, Deepak Choudhary
OBJECTIVE: The aim of present research work was to develop a herbal fast disintegrating tablet containing Fagonia schweinfurthii Hadidi dried extract and determining its antihistaminic activity using guinea pig ileum. METHOD: The tablets were formulated by wet granulation technique using three different superdisintegrants (croscarmillose, crospovidone and sodium starch glycolate) at three different use levels. The tablets were evaluated for various physical properties like hardness, friability weight variation etc...
March 9, 2018: Current Clinical Pharmacology
Chistiane Mendes Feitosa, George Layson da Silva Oliveira, Antonio do Nascimento Cavalcante, Soane Kaline Morais Chaves, Mahendra Rai
Oxidative stress is a major mechanism underlying the development of various neurodegenerative diseases (Alzheimer, Parkinson, Huntington and amyotrophic lateral sclerosis). Excessive formation of reactive oxygen species (ROS) and nitrogen (RNSs) can overburden the ability of the enzymatic antioxidant defense mechanisms (superoxide dismutase, catalase and glutathione reductase) and non-enzymatic (uric acid, ascorbic acid, α-tocopherol and reduced glutathione) causing the development of oxidative stress and consequently impairing the neuronal system cells by means of oxidative damage to a variety of important biological molecules such as lipids, DNA and proteins...
February 28, 2018: Current Clinical Pharmacology
Arduino A Mangoni, Elzbieta A Jarmuzewska
No abstract text is available yet for this article.
2018: Current Clinical Pharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"